Banyan Treatment Centers and HoloMD Reveal Promising 90-Day Pilot Results for AI-Driven Post-Discharge Recovery Care
In a significant step forward for post-discharge recovery care, Banyan Treatment Centers, a national leader in substance use disorder and co-occurring mental health treatment, has partnered with HoloMD, an innovator in Continuous Precision Psychiatry, to evaluate a new approach to patient monitoring and engagement following discharge from structured treatment programs. The companies have announced the results of a 90-day pilot program centered on the Banyan Companion™, a solution designed to bridge the critical gap between clinical care and real-world recovery.
The pilot, conducted at Banyan Treatment Centers Texas, focused on a high-acuity recovery population—individuals at heightened risk of relapse after leaving structured care environments. This transitional period is widely recognized as one of the most vulnerable phases in recovery, as patients move from intensive, supervised care to greater independence. Traditional care models, which often rely on periodic follow-up visits, can struggle to provide sufficient visibility into patients’ day-to-day mental and emotional states during this time.
To address this challenge, the pilot leveraged HoloMD’s between-visit monitoring model, which combines artificial intelligence with human clinical oversight. The approach enables continuous engagement with patients, allowing for early identification of risk signals and timely intervention when needed.
Strong Enrollment and Sustained Engagement
The results of the 90-day pilot highlight both strong patient participation and sustained engagement—key indicators of feasibility and acceptance in real-world settings.
A notable 90.1% of eligible discharged clients chose to enroll in the program at the time of discharge, suggesting a high level of trust and willingness among patients to adopt technology-supported recovery tools. Of those enrolled, 89% accepted the platform’s terms and initiated monitoring, demonstrating a smooth onboarding process and minimal friction in adoption.
Importantly, engagement remained high throughout the pilot period. Approximately 83% of participants stayed active on the platform, indicating that the solution was not only accessible but also meaningful and relevant to users during their recovery journey.
Actionable Insights and Safety Validation
Beyond engagement metrics, the pilot provided valuable insights into patient safety and clinical responsiveness. Among monitored clients, 36% generated at least one actionable escalation—events or signals that warranted attention from clinical teams. This finding underscores the platform’s ability to surface meaningful risk indicators that might otherwise go unnoticed in traditional care models.
In total, 19 Human + AI-generated clinical alerts required review or direct intervention by Banyan’s clinical staff. These alerts spanned a range of categories, reflecting the complex and multifaceted nature of recovery:
- 8 alerts related to clinical deterioration
- 3 alerts associated with relapse risk or occurrence
- 2 formal complaints
- 1 acute stressor or significant loss event
- 5 additional updates relevant to patient safety
Each alert was processed through HoloMD’s human-in-the-loop (HITL) safety oversight framework. This approach ensures that AI-generated insights are reviewed and validated by trained professionals before action is taken, combining the speed and scalability of technology with the judgment and empathy of human clinicians.
Alerts were escalated to Banyan’s alumni and clinical teams as appropriate, enabling targeted and timely interventions tailored to individual patient needs.
Real-Time Re-Engagement: A Critical Case Example
One of the most compelling demonstrations of the platform’s value came in the form of a real-world re-engagement scenario during the pilot.
A patient who had been inactive on the platform for more than six weeks suddenly disclosed a relapse, triggered by the loss of a loved one. In traditional care settings, such a development might go unnoticed until a scheduled follow-up visit—potentially weeks later.
However, through the Banyan Companion™ platform, the disclosure was immediately captured and flagged. Within approximately 20 minutes, Banyan’s clinical team initiated outreach and began re-engagement efforts.
This rapid response highlights the transformative potential of continuous monitoring. By maintaining an always-on connection with patients, the system enables care teams to intervene at critical moments—when support is most urgently needed.
Bridging the Post-Discharge Gap
The pilot results emphasize the importance of addressing the “in-between” moments in care—periods when patients are outside clinical settings but still navigating significant challenges. Relapse, emotional distress, and other high-risk events often occur between scheduled appointments, where traditional models offer limited visibility.
By extending clinical reach beyond facility walls, the Banyan Companion™ creates a continuity-of-care bridge that supports patients in real time. This model shifts care from reactive to proactive, allowing clinicians to identify and address issues before they escalate into crises.
Leadership Perspectives
Dr. Bruce Kehr, Founder and CEO of HoloMD, emphasized the importance of combining advanced technology with human insight.
“High-risk events occur between clinic visits,” he said. “By integrating compassionate AI engagement with human clinical oversight, we can surface meaningful risk signals early and support timely, data-informed interventions that are both precise and effective.”
John Sory, CEO of Banyan Treatment Centers, highlighted the role of connection in long-term recovery.
“Maintaining connection after discharge is central to relapse prevention,” Sory noted. “This pilot demonstrates how technology can extend our clinical reach, strengthen patient safety, and enhance continuity of care during some of the most vulnerable periods in a patient’s journey.”
Implications for the Future of Recovery Care
The success of the 90-day pilot suggests broader implications for the future of behavioral health and recovery management. As healthcare systems increasingly adopt digital tools, solutions like the Banyan Companion™ could play a pivotal role in reshaping how care is delivered beyond traditional settings.
Key takeaways from the pilot include:
- High patient acceptance of AI-supported monitoring tools
- Sustained engagement, even among high-acuity populations
- Early detection of risk, enabling proactive intervention
- Enhanced clinical efficiency through targeted alerts and prioritization
- Improved continuity of care, bridging the gap between discharge and long-term recovery
While further research and scaling efforts will be needed, the findings point to a promising model for integrating AI into behavioral healthcare in a way that enhances—not replaces—human care.
Conclusion
The collaboration between Banyan Treatment Centers and HoloMD demonstrates how technology can meaningfully improve outcomes in one of the most challenging phases of recovery. By combining continuous monitoring, AI-driven insights, and human clinical oversight, the pilot offers a new blueprint for supporting patients beyond discharge.
As healthcare continues to evolve, approaches that prioritize connection, responsiveness, and personalized care are likely to become increasingly central. The Banyan Companion™ pilot provides a compelling example of how innovation can be harnessed to meet these needs—ultimately helping more individuals achieve sustained recovery and improved quality of life.
About Banyan Treatment Centers
Banyan Treatment Centers is a national provider of substance use disorder and co-occurring mental health treatment services. With multiple locations across the United States, Banyan offers inpatient, residential, partial hospitalization, and outpatient programs grounded in evidence-based, patient-centered care
About HoloMD
HoloMD provides the Human+AI infrastructure layer for Continuous Precision Psychiatry monitoring and reporting. Through Remote Therapeutic Monitoring (RTM) workflows and structured oversight processes, HoloMD enables early risk detection, reimbursed between-visit care, and actionable insights that strengthen long-term recovery outcomes.
